Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec;46(Suppl 1):e33.
doi: 10.12771/emj.2023.e33. Epub 2023 Dec 31.

Updates on Obesity in Prader-Willi Syndrome: From Genetics to Management

Affiliations
Review

Updates on Obesity in Prader-Willi Syndrome: From Genetics to Management

Young Bae Sohn et al. Ewha Med J. 2023 Dec.

Abstract

Prader-Willi syndrome (PWS), which is considered the most common genetic form of obesity, results from the absence of imprinted genes in the paternally derived PWS critical region located on chromosome 15q11.2-13. Infants with PWS exhibit poor sucking, neonatal hypotonia, and delayed motor milestones. These patients begin to experience hyperphagia and obesity from 2 to 3 years of age. PWS is a multisystemic disorder, and its clinical manifestations include developmental delay/intellectual disability, behavioral problems, dysmorphic facial features, short stature, scoliosis, and endocrine abnormalities such as hypogonadism, growth hormone deficiency, hypothyroidism, and central adrenal insufficiency. Although the underlying mechanism of hyperphagia is not completely understood, hypothalamic and endocrine dysregulation is believed to be responsible for the lack of satiety and abnormal food-seeking behaviors that lead to severe obesity. The management of PWS requires a multidisciplinary team approach. Early diagnosis and comprehensive early intervention are essential to prevent the development of obesity-related morbidities, including metabolic syndrome, diabetes mellitus, obstructive sleep apnea, respiratory failure, pulmonary hypertension, and cardiovascular complications. Although several clinical trials have been conducted on the pharmacologic treatment of obesity in PWS, no drugs have demonstrated a consistently beneficial effect to date. Nevertheless, ongoing research efforts should be directed toward understanding the mechanism of the unique obesity phenotype of PWS and developing pharmacological therapies.

Keywords: Genomic imprinting; Hyperphagia, obesity; Prader-Willi syndrome.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1.
Fig. 1.. Endocrine changes in Prader-Willi syndrome. Changes in orexigenic and anorexigenic hormone levels in PWS. ↑, increased; ↓, decreased; =, unchanged; GLP-1, glucagon-like peptide 1; PYY, peptide YY; BDNF, brain-derived neurotrophic factor; PWS, Prader-Willi syndrome.

References

    1. Butler MG, Miller JL, Forster JL. Prader-Willi syndrome: clinical genetics, diagnosis and treatment approaches: an update. Curr Pediatr Rev. 2019;15(4):207–244. doi: 10.2174/1573396315666190716120925. - DOI - PMC - PubMed
    1. Poitou C, Mosbah H, Clément K. MECHANISMS IN ENDOCRINOLOGY: update on treatments for patients with genetic obesity. Eur J Endocrinol. 2020;183(5):R149–R166. doi: 10.1530/EJE-20-0363. - DOI - PubMed
    1. Butler MG. Prader–Willi syndrome and chromosome 15q11.2 BP1-BP2 region: a review. Int J Mol Sci. 2023;24(5):4271. doi: 10.3390/ijms24054271. - DOI - PMC - PubMed
    1. Sohn YB. Genetic obesity: an update with emerging therapeutic approaches. Ann Pediatr Endocrinol Metab. 2022;27(3):169–175. doi: 10.6065/apem.2244188.094. - DOI - PMC - PubMed
    1. Angulo MA, Butler MG, Cataletto ME. Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings. J Endocrinol Invest. 2015;38(12):1249–1263. doi: 10.1007/s40618-015-0312-9. - DOI - PMC - PubMed

LinkOut - more resources